European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01239589
First received: November 10, 2010
Last updated: March 28, 2011
Last verified: March 2011
  Purpose

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.


Condition
Acute Bipolar Manic Episode

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Length of hospital stay [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Use of resources [ Designated as safety issue: No ]
  • Treatments used [ Designated as safety issue: No ]
  • Demographics [ Designated as safety issue: No ]

Enrollment: 1280
Study Start Date: November 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
2
patients admitted as for an acute bipolar manic episode and treated with quetiapine XR

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients diagnosed with Bipolar Disorder (ICD-10).admitted due to a acute manic episode and treated with quetiapine IR or quetiapine XR during the hospitalization period

Criteria

Inclusion Criteria:

  • Patients diagnosed with Bipolar Disorder (ICD-10).
  • Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
  • Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria:

  • Patients in which BD is not the main reason for hospitalization
  • Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
  • Patients receiving both quetiapine IR and XR during the same hospitalization period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01239589

  Hide Study Locations
Locations
Belgium
Research Site
Assebroek, Belgium
Research Site
Bertrix, Belgium
Research Site
Brugge, Belgium
Research Site
Elsene, Belgium
Research Site
Gent, Belgium
Research Site
Godinne, Belgium
Research Site
Koksijde, Belgium
Research Site
Malle, Belgium
Research Site
Marchienne-au-Pont, Belgium
Research Site
Montignies-Sur-Sambre, Belgium
Research Site
Ottignies, Belgium
Research Site
Overpelt, Belgium
Research Site
Roeselaere, Belgium
Croatia
Research Site
Split, Croatia
Research Site
Zagreb, Croatia
Denmark
Research Site
Augustenborg, Denmark
Research Site
Bispebjerg, Denmark
Research Site
Br�nderslev, Denmark
Research Site
Odense, Denmark
Finland
Research Site
Helsingin Kaupunki, Finland
Research Site
Jyv�skyl�, Finland
Research Site
Kellokoski, Finland
Research Site
Tammisaari, Finland
Germany
Research Site
Ulm, Baden-W�rttemberg, Germany
Research Site
Cham, Bayern, Germany
Research Site
Neu�tting, Bayern, Germany
Research Site
Regensburg, Bayern, Germany
Research Site
Wasserburg am Inn, Bayern, Germany
Research Site
W�rzburg, Bayern, Germany
Research Site
Greifswald, Mecklenburg- Vorpommern, Germany
Research Site
Bielefeld, Niedersachsen, Germany
Research Site
Hildesheim, Niedersachsen, Germany
Research Site
Liebenburg, Niedersachsen, Germany
Research Site
Bochum, Nordrhein-Westfalen, Germany
Research Site
Berlin, Germany
Italy
Research Site
Ceglie Messapica, Brindisi, Italy
Research Site
San Pietro Vernotico, Brindisi, Italy
Research Site
Lamezia Terme, Catanzaro, Italy
Research Site
Loc. S. Marciano (Sora), Frosinone, Italy
Research Site
S. Agata Militello, Messina, Italy
Research Site
Conegliano, Treviso, Italy
Research Site
Ascoli Piceno, Italy
Research Site
Bologna, Italy
Research Site
Cosenza, Italy
Research Site
Cuneo, Italy
Research Site
Ferrara, Italy
Research Site
Foggia, Italy
Research Site
Mestre, Italy
Research Site
Pisa, Italy
Research Site
Roma, Italy
Research Site
Sassari, Italy
Research Site
Teramo, Italy
Turkey
Research Site
Adana, Turkey
Research Site
Ankara, Turkey
Research Site
Ayd?n, Turkey
Research Site
Bolu, Turkey
Research Site
Diyarbakir, Turkey
Research Site
Elazig, Turkey
Research Site
Erzurum, Turkey
Research Site
Istanbul, Turkey
Research Site
Kayseri, Turkey
Research Site
Konya, Turkey
Research Site
Manisa, Turkey
Research Site
Samsun, Turkey
Research Site
Sanliurfa, Turkey
Research Site
Sivas, Turkey
Research Site
Trabzon, Turkey
Research Site
Zonguldak, Turkey
United Kingdom
Research Site
Winsford, Cheshire, United Kingdom
Research Site
Dartford, Kent, United Kingdom
Research Site
Ealing, London, United Kingdom
Research Site
Prescot, Merseyside, United Kingdom
Research Site
Norwich, Norfolk, United Kingdom
Research Site
Taunton, Somerset, United Kingdom
Research Site
Cannock, Staffordshire, United Kingdom
Research Site
Chertsey, Surrey, United Kingdom
Research Site
Wolverhampton, West Midlands, United Kingdom
Research Site
Pulborough, West Sussex, United Kingdom
Research Site
Bradford, Yorkshire, United Kingdom
Research Site
Bury St Edmunds, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Hull, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
Leicester, United Kingdom
Research Site
London, United Kingdom
Research Site
Newcastle (Upon Tyne), United Kingdom
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT01239589     History of Changes
Other Study ID Numbers: NIS-NEU-SER-2010/1
Study First Received: November 10, 2010
Last Updated: March 28, 2011
Health Authority: Belgium: Institutional Review Board
Croatia: Agency for Medicinal Product and Medical Devices
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices (informed)
Italy: Ethics Committee
Denmark: Danish Medicines Agency
Finland: Ethics Committee
Turkey: Ethics Committee (informed)
United Kingdom: Research Ethics Committee

Keywords provided by AstraZeneca:
Patients admitted as for an acute bipolar manic episode
Description of management patterns and hospital stay in patients admitted for acute bipolar manic episode and treated with either quetiapine IR or quetiapine XR

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 22, 2014